This story clearly outlines how a study of mammography screening in Norway feeds into debate about the value of breast cancer screening. It includes the comments of experts who have a variety of perspectives on the latest data.
Women have been whipsawed by often confusing statements and claims about whether and when to get a mammogram. This story lays out how the latest study data points to benefits of screening… but that the benefits appear to be smaller than most people believe.
The story does not mention the cost of mammography (or of follow up tests and treatments) to the individual, or, collectively, to society. Based on the results of this study, 2,500 women would have to be screened every other year for a decade in order to prevent one death from breast cancer.
As the story points out, during that same time 1,000 of those women would have at least one false alarm and 500 would undergo an unnecessary biopsy, thus adding to the price tag.
The story reports both the 10 percent reduction in breast cancer deaths that the researchers attributed to screening, as well as the calculation that 2,500 women would have to be screened for a decade to prevent one breast cancer death.
The story points out that there are many false alarms among women who are screened with mammography and that most of the cancers that are found and treated would not have been lethal. It notes calculations from an editorial accompanying the study that for every breast cancer death prevented five or more women are treated for tumors that would never have become lethal.
The story accurately describes the study and highlights some of the advantages of the methods used in this study compared to earlier studies. We wish it had mentioned some of the limitations of the observational methods used. For instance, the researchers mentioned that a longer study may have found a larger benefit to screening. Nonetheless, we’ll give it the benefit of the doubt on this criterion.
The story does not exaggerate the threat of breast cancer and emphasizes that this study and others indicate that the effect of mammography screening is more modest than most women believe.
The story includes more than one independent source. However, the story does not tell readers the sources of funding, which were the Cancer Registry of Norway and the Research Council of Norway.
The story highlights experts talking about the decision about whether or not to get screening mammograms, and therefore addresses even the option of foregoing mammograms.
Although the availability of mammography is not at issue in this story, it could have pointed out that the researchers attributed most of the decrease in breast cancer deaths to multidisciplinary breast cancer management teams. While all the women screened by mammography in Norway had access to these expert teams, women in the U.S. who get mammography may not have access to this sort of treatment support.
In this case, the novelty of the approach is the study method. The story reports that Norway provided researchers with a unique opportunity, since mammography screening was phased in over a nine year period, thus allowing researchers to compare the outcomes of women who were screened to similar women who were not.
The story includes interviews and other information that does not appear to come from a news release.
Systematic, Criteria-Driven
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like